8-K 1 a4741505.txt PROGENICS PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 14, 2004 Progenics Pharmaceuticals, Inc. ----------------------------------------------------- (Exact name of registrant as specified in its charter) Delaware 000-23143 13-3379479 ---------------------------- ----------------- --------------------------- (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 777 Old Saw Mill River Road, Tarrytown, New York 10591 ------------------------------------------------------------------------ (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (914) 789-2800 ----------------- ---------------------------------------------------------------- (Former name or former address, if changed since last report.) Section 8 - Other Events Item 8.01 Other Events Progenics announced the appointment of Alton B. Kremer, M.D., Ph.D. to Vice President, Clinical Research, a newly created position in the Company. Dr. Kremer will be responsible for medical aspects of the Company's clinical trials. Section 9 - Financial Statements and Exhibits Item 9.01 Financial Statement and Exhibits (c) the following exhibits are filed with this report Exhibit Number Description 99.1 Press release dated October 14, 2004 ---------------- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROGENICS PHARMACEUTICALS, INC. By: /s/ ROBERT A. MCKINNEY ------------------------------------------- Robert A. McKinney Vice President, Finance & Operations Date: October 14, 2004